KR940703814A - 히스타민 H3 작용제/길항제로서의 이미다졸릴-알킬-피페라진 및 -디아제핀 유도체(Imidazolyl-alkyl-piperazine and-diazepine derivatives as histamine H3 agonists/antagonists) - Google Patents

히스타민 H3 작용제/길항제로서의 이미다졸릴-알킬-피페라진 및 -디아제핀 유도체(Imidazolyl-alkyl-piperazine and-diazepine derivatives as histamine H3 agonists/antagonists)

Info

Publication number
KR940703814A
KR940703814A KR1019940702060A KR19940702060A KR940703814A KR 940703814 A KR940703814 A KR 940703814A KR 1019940702060 A KR1019940702060 A KR 1019940702060A KR 19940702060 A KR19940702060 A KR 19940702060A KR 940703814 A KR940703814 A KR 940703814A
Authority
KR
South Korea
Prior art keywords
compound
group
alkyl
independently selected
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019940702060A
Other languages
English (en)
Korean (ko)
Inventor
시 냉-양
Original Assignee
에릭 에스.딕커
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에릭 에스.딕커, 쉐링 코포레이션 filed Critical 에릭 에스.딕커
Publication of KR940703814A publication Critical patent/KR940703814A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1019940702060A 1991-12-18 1992-12-16 히스타민 H3 작용제/길항제로서의 이미다졸릴-알킬-피페라진 및 -디아제핀 유도체(Imidazolyl-alkyl-piperazine and-diazepine derivatives as histamine H3 agonists/antagonists) Withdrawn KR940703814A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81064291A 1991-12-18 1991-12-18
US07/810,642 1991-12-18
PCT/US1992/010697 WO1993012093A1 (en) 1991-12-18 1992-12-16 Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists

Publications (1)

Publication Number Publication Date
KR940703814A true KR940703814A (ko) 1994-12-12

Family

ID=25204324

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019940702060A Withdrawn KR940703814A (ko) 1991-12-18 1992-12-16 히스타민 H3 작용제/길항제로서의 이미다졸릴-알킬-피페라진 및 -디아제핀 유도체(Imidazolyl-alkyl-piperazine and-diazepine derivatives as histamine H3 agonists/antagonists)
KR94702060A Expired - Fee Related KR0136207B1 (en) 1991-12-18 1994-06-16 Imidazolyl-alkyl-piperazine and diazepine derivatives as histamine h3 agonists/antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR94702060A Expired - Fee Related KR0136207B1 (en) 1991-12-18 1994-06-16 Imidazolyl-alkyl-piperazine and diazepine derivatives as histamine h3 agonists/antagonists

Country Status (17)

Country Link
EP (1) EP0618905B1 (https=)
JP (1) JP2540015B2 (https=)
KR (2) KR940703814A (https=)
AT (1) ATE128708T1 (https=)
AU (1) AU662588B2 (https=)
CA (1) CA2125964C (https=)
DE (1) DE69205287T2 (https=)
DK (1) DK0618905T3 (https=)
ES (1) ES2078118T3 (https=)
GR (1) GR3018474T3 (https=)
HK (1) HK185696A (https=)
IL (1) IL104126A (https=)
MY (1) MY108119A (https=)
NZ (1) NZ246295A (https=)
TW (1) TW268951B (https=)
WO (1) WO1993012093A1 (https=)
ZA (1) ZA929786B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633376A (en) * 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
US5633377A (en) * 1990-12-28 1997-05-27 Neurogen Corporation 4-piperidino- and piperazinomethyl-2-cyclohexyl imidazole derivatives; dopamine receptor subtype specific ligands
US5646280A (en) * 1990-12-28 1997-07-08 Neurogen Corporation Substituted 4-(alkyl, dialkyl) or cycloaklyl)aminomethyl 2-phenylimidazoes: dopamine receptor subtype specific ligands
EP0582164B1 (en) * 1992-07-31 1998-12-23 Bristol-Myers Squibb Company Adenosine re-uptake inhibiting derivatives of diphenyl oxazoles, thiazoles and imidazoles
DE4311968A1 (de) * 1993-04-10 1994-10-20 Hoechst Ag Smektische Flüssigkristallmischung
DK0841923T3 (da) * 1995-06-07 2003-01-27 Gliatech Inc 1H-4(5)-substituerede imidazolderivater
US6072057A (en) * 1996-06-06 2000-06-06 Gliatech Inc. 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
JP2002534511A (ja) 1999-01-18 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 置換型イミダゾール、それらの調製及び使用
US6211182B1 (en) * 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
TW575561B (en) * 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
WO2002024657A2 (en) 2000-09-20 2002-03-28 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
ATE283853T1 (de) 2000-09-20 2004-12-15 Schering Corp Substituierte imidazole als duale histamine h1 und h3 agonisten oder antagonisten
AU2001292723A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
AR030946A1 (es) 2000-09-20 2003-09-03 Schering Corp Derivados de imidazoles sustituidos un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos como agonistas o antagonistas duales de h1 y h3 de histamina
FR2827863A1 (fr) * 2001-07-27 2003-01-31 Sanofi Synthelabo Derives d'aminoalkylimidazole, leur preparation et leur utilisation en therapeutique
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
KR20100028168A (ko) * 2008-09-04 2010-03-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 발광재료로서 채용하고 있는 유기 발광 소자
WO2010133544A1 (en) * 2009-05-22 2010-11-25 Evotec Ag Piperazine and aminopyrrolidine compounds as histamine h3 receptor antagonists
JP5407841B2 (ja) * 2009-12-24 2014-02-05 信越化学工業株式会社 反応性シリル基を有するトリアリールアミン誘導体及び無機材料並びに色素増感型光電変換素子
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2586562B1 (fr) * 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
US4829065A (en) * 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
FR2630328B1 (fr) * 1988-04-22 1990-08-24 Inst Nat Sante Rech Med Derive de l'histamine, sa preparation et son application en therapeutique
FR2661909B1 (fr) * 1990-05-09 1997-08-14 Inst Nat Sante Rech Med Nouveaux composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation.

Also Published As

Publication number Publication date
MY108119A (en) 1996-08-15
DE69205287D1 (de) 1995-11-09
IL104126A0 (en) 1993-05-13
GR3018474T3 (en) 1996-03-31
DK0618905T3 (da) 1995-12-04
TW268951B (https=) 1996-01-21
CA2125964A1 (en) 1993-06-24
ES2078118T3 (es) 1995-12-01
EP0618905A1 (en) 1994-10-12
AU3247793A (en) 1993-07-19
ATE128708T1 (de) 1995-10-15
HK185696A (en) 1996-10-11
DE69205287T2 (de) 1996-03-14
WO1993012093A1 (en) 1993-06-24
IL104126A (en) 1999-05-09
ZA929786B (en) 1993-06-18
EP0618905B1 (en) 1995-10-04
KR0136207B1 (en) 1998-04-25
AU662588B2 (en) 1995-09-07
CA2125964C (en) 2001-06-19
NZ246295A (en) 1996-06-25
JPH06511251A (ja) 1994-12-15
JP2540015B2 (ja) 1996-10-02

Similar Documents

Publication Publication Date Title
KR940703814A (ko) 히스타민 H3 작용제/길항제로서의 이미다졸릴-알킬-피페라진 및 -디아제핀 유도체(Imidazolyl-alkyl-piperazine and-diazepine derivatives as histamine H3 agonists/antagonists)
DE69724108T2 (de) Isochinolinderivate und arzneimittel
JPS6354321A (ja) 血糖降下剤
CA2505368A1 (en) Trans-9,10-dehydroepothilone c and d, analogs thereof and methods of making the same
KR0142802B1 (en) Imidazolyl or imidazolalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
KR910015562A (ko) 뇌부전 질환치료용 약제, 신규 2-(1-피페라지닐)-4-페닐시클로알카노 피리미딘 유도체, 및 그의 제법
DE69212164D1 (de) Imidolylalkyl-derivate substituiert mit einem stickstoffenthaltende-6 gliedrigen ring
JP3053490B2 (ja) チアゾリジン−２，４−ジオン誘導体とその塩及び製造法
KR900006307A (ko) 단백질 키나아제 c억제제로서 유용한 신규 퀴놀릴옥사졸-2-온
CN87100171A (zh) 新茚并噻唑衍生物及其制备方法
JPS6340784B2 (https=)
DE2142912A1 (de) Neue Bis-benzopyranverbindungen und Verfahren zu ihrer Herstellung
KR910000647A (ko) 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도
CA2452920A1 (en) Benzo [g] quinoline derivatives for treating glaucoma and myopia
EP1373234B1 (de) Urokinase-inhibitoren
NO165195C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nye derivater av 4,5-dihydro-oksazolyl-2-((2-pyridyl)-metyl-tio- eller metylsulfinyl)-benz- eller tienoimidazoler.
JP2009538909A (ja) ５‐ヒドロキシトリプタミン‐６リガンドとしてのベンゾオキサゾールおよびベンゾチアゾール誘導体
JPS6137784A (ja) 免疫調整剤としての２‐ベンジル‐４‐（４‐ピリジル）チアゾール類及びその誘導体
JPH02233677A (ja) 新規な１―〔３―（２―ヒドロキシ―３―アルキルアミノプロポキシ）―２―チエニル〕―３―フェニル―１―プロパノン類及びその製造方法
KR890005094A (ko) 치환된 3-아미노시드논이민, 이의 제조방법 및 이의 용도
WO2022033303A1 (zh) 苄胺类衍生物及其制备方法与用途
EP0898567B1 (en) N-aminoalkyl-1-biphenylenyl-2-carboxamides; dopamine receptor subtype specific ligands
KR940005621A (ko) 벤조[b]티오펜-3-일-피페라진. 이의 제조방법 및 약제로서 이의 용도
US2339914A (en) Chemical compound
US2851393A (en) Beta-diethylamino butyric acid anilide, nontoxic salts thereof and aqueous local anesthetic solutions therewith

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20010122

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20010122

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000